Storia della carriera di David J. Valacer
Precedenti posizioni note di David J. Valacer
Società | Posizione | Inizio | Fine |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Direttore Tecnico/Scientifico/R&S | 01/08/2017 | 20/10/2017 |
Weill Cornell Medical College | Corporate Officer/Principal | - | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Direttore Tecnico/Scientifico/R&S | 01/01/2014 | - |
Formazione di David J. Valacer
New York University | Graduate Degree |
University of Vermont College of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Graduate Degree | 1 |
Corporate Officer/Principal | 1 |
Settori
Consumer Services | 4 |
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
- Borsa valori
- Insiders
- David J. Valacer
- Esperienza